@16:18+ Dr. Weiner talks about how the beauty of dosing anti CD3 orally or nasally is from this being a completely natural route. The human body is simply not designed to take antibodies directly into the veins, but instead through the signalling pathways. Dr. Weiner says that dosing like this will result in NO toxicity. (Read that again!) They really are confident that they have cracked the safety issues with this new, patented, dosing platform. Pure, absolute, genius!
TILS: I am in complete awe of your work. I also have friends & family who will absolutely benefit from Foralumab for various reasons, which makes me something more than just an investor here. Best of luck!
@27:00+ Dr. Shailubhai said that the fact that Covid patients in the Brazil trial regained their sense of smell so quickly pretty much confirms Dr. Weiner’s underlying hypothesis that nasal Foralumab would up regulate T-Regs and normalise immunity via the human signalling pathway. There must be absolutely nothing more satisfying for a scientist than having a theoretical hypothesis proven so well with such a simple measurement as sense of smell, which makes it even more assuring that Foralumab works exactly as designed! That’s why they got so excited after those Brazil results.
Sorry, but that took me an awful long time to find again: Erm, oops... I may have got it wrong myself, that’s egg on my face. See what you think?: @16:57+ Dr. Shailubhai says that “we are already beginning in a couple of weeks nasal administration of Foralumab for the expanded program...” Actually, that does sound like he was talking about that MS patient, perhaps I got too excited at that point and my brain switched into Covid trial mode. Doh! Apologies everyone. I admit it wasn’t the clearest of videos to listen to, ...but still MANY positive takeaways.
To all LTH: I expect that within 3-4 months, from what Dr. Weiner was saying, he hopes to have CT brain scans for that one expanded access patient, proving that Foralumab is efficacious in the brain and acting to reduce inflammation and improve the brain immune response. He sounds very confident in this result! When this happens TILS will be in a different league, and no amount of deramping will hold this rocket back! (We may also have some initial results back from the Phase 2 covid trials as well!) :))) Regards,
WRONG!, Dr. Shailubhai said the additional animal testing could be run IN PARALLEL and that they have more than enough safety data. There have already been 3 phase 1 trials now for Foralumab with real patients and the Covid phase 2 is starting within 2 weeks. MS phase 2 will start after the expanded access with 1 patient which lasts 3 months. There’s only one definition of IN PARALLEL that I am aware of, or do all you derampers speak a different language!
Many thanks @ctfyfe. I also am extremely positive after that call.
Although I just can’t bring myself to point out all the complete and utter rubbish, twists, half-truths and misleading statements that @sangijuelas1 was spirting out (everyone can watch the video for themselves to see what a complete paid/fake that guy is), there were a few slightly obfuscated take-aways :
-They have finished enough Phase 1 trials now with Foralumab to absolutely prove both its safety and efficacy. -IN PARALLEL with the follow-on phase 2 trials for Foralumab (ie NO holdup) there will be some additional animal trials to meet standard FDA requirements, but as they already dosed animals 3 times a day for a year there will be NO SURPRISES! and this is just a tick in the box, endpoints at, 1, 3 and 6 months (ie 6 months in total). -The phase 2 Foralumab trial for MS will start straight after that expanded access for 1 patient (I think that was for 3 months, someone correct me if I am wrong?). -THE PHASE 2 TRIAL FOR COVID WILL START WITHIN 2 WEEKS!!! Great news!
A re-post from another BB: A very worrying find for Covid patients, but more evidence to suggest that Foralumab could also be very effective for long Covid sufferers! (Note the reference to Lupus in the article.)
We urgently need a safer and more targeted/efficacious way to dose ALL mAbs, like the patented TILS platform! The results from the Brazil trial proved the TILS platform works, irrespective of the additional fantastic results for Foralumab (87% less lung damage). Come on TILS.
Well it’s a classic de-ramp tactic to bash the BOD.
I don’t know any share that has had a significant patent application granted where the share price hasn’t increased significantly. Patents are a defining contribution to share value. In fact I feel so strongly now that this share is being manipulated I may even take it up with the FCA.